100   ^a20200614d2014    k  y0porb0103    ba
101 0 ^aeng
102   ^aPT
200 1 ^aPharmaceutical research on children in Germany^fBernd-Rüdiger Kern
305   ^aComunicação apresentada na IV EAHL Conference on European Law and Patient Safety, Coimbra  (9-11 October, 2013)
330   ^aI. Introduction. II. The basic decisions of the German Medicinal Products Act. 1. The balance between benefits and risks. 2. Groups of cases. III. Research on minors.1. Objective conditions. a) Indicated medical treatment (§ 41 sec. 2 s.1 nr. 1 AMG). b) Relative indicated medical treatment (§ 40 sec. 4 AMG). c) Non-indicated treatments: benefit to the group of patients (§ 41 sec. 2 s. 1 nr. 2 AMG). 2. Medical information and consent. a) Consent. b) Medical information. IV. Conclusion
461  1^tLex medicinae^cCoimbra^bCoimbra Editora^x1646-0359^vN.º Especial (2014)^pp. 243-248
606   ^aMedicina
606   ^aInvestigação farmacêutica
606   ^aMedicamento
606   ^aCriança
606   ^aEnsaio clínico
607   ^aAlemanha
700  1^aKern,^bBernd-Rüdiger
856   ^uhttps://www.law.lu.se/webuk.nsf/(MenuItemByDocId)/IDFB83BA04C3156F72C1257C750076399D/$FILE/Lex%20Medicinae%20001-292.pdf^zClique aqui para aceder à revista
920 n
921 a
922 a
923  
924  
925  
931 20200614
932 d
933 2014
934 
935 k  
936 y
937 0
938 ba